Hemispherx Biopharma (HEB) 0.29 $HEB
Stock to Watch: Hemispherx Biopharma Up 8.0% (HEB)
Comtex SmarTrend(R) - Tue Jul 22, 10:09AM CDT
Hemispherx Biopharma (AMEX:HEB) is one of today's best performing penny stocks, up 8.0% to $0.28 on 1.2x average daily volume. Hemispherx Biopharma has traded 831,000 shares thus far today, vs. average volume of 666,000 shares per day. The stock has outperformed the Dow (8.8% to the Dow's 0.4%) and outperformed the S&P 500 (8.8% to the S&P's 0.5%) during today's trading.
Hemispherx Achieves High Ranking in Sensitivity Testing Against MERS/SARS Coronaviruses Compared to Other Drugs
GlobeNewswire - Tue Jul 22, 7:31AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) announced that a new publication abstract in Infectious Disorder Drug Targets (2014 Jul 13. [Epub ahead of print]) is available for review as described in PubMed on July 16, 2014, and proposes that the Middle East Respiratory Syndrome (MERS)/(Severe Acute Respiratory Syndrome) SARS coronaviruses (CoV) may be most effectively inhibited by interferons (IFNs) and an IFN inducer (http://www.ncbi.nlm.nih.gov/pubmed/?term=Sensitivity+of+SARS%2FMERS+CoV+to+Interferons+and+Other+Drugs+Based+on+Achievable+Serum+Concentrations+in+Humans). The article, entitled "Sensitivity of SARS/MERS CoV to Interferons and Other Drugs Based on Achievable Serum Concentrations in Humans", is authored by Hemispherx scientists. It is suggested that correcting a viral induced defect in immunity may be the first significant way to decrease MERS/SARS associated mortality.
Hemispherx Biopharma and Bioclones, a Leading South African Biotechnology Company, Join Forces on Novel Therapeutic Cancer Vaccine
GlobeNewswire - Mon Jul 14, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announced a strategic alliance to develop multiple projects with Bioclones (Pty) Ltd. ("Bioclones" , a leading South African biotechnology company.
Hemispherx Biopharma and Bioclones Join Forces in Effort to Eradicate HIV/AIDS Virus Based on Recent Clinical Insights of Wistar Institute, University of Pennsylvania
GlobeNewswire - Tue Jul 08, 8:23AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , announced execution of an agreement to seek South African government approval to initiate a study of Alferon(R) N, the only FDA approved natural interferon, in the suppression of HIV Type 1 replication and the reduction/elimination of functional cell-associated HIV DNA integration (latent HIV). The study is contemplated as part of a broad strategic alliance with Bioclones (Pty) Ltd. ("Bioclones" , a leading South African biotechnology company.
Hemispherx Biopharma to Present During the 2014 BIO International Convention June 26
GlobeNewswire - Wed Jun 25, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , will present a corporate update on their Advanced Therapies for the Human Immune System at 9:45 a.m. Pacific Time on June 26, during the 2014 BIO International Convention at the San Diego Convention Center.
5 Stocks Poised for Breakouts
at The Street - Fri Jun 13, 12:22PM CDT
These stocks look ready to break out and trade higher from current levels.
Hemispherx Announces That the University of Texas Medical Branch Confirms Activity of Alferon(R) N Against MERS (Middle East Respiratory Syndrome) Virus
GlobeNewswire - Tue Jun 03, 12:07PM CDT
Hemispherx Biopharma (NYSE MKT:HEB) announced that it has confirmed that one of its advanced stage biological products, Alferon(R) N, inhibits replication of the MERS virus in vitro. Chien-Te (Kent) Tseng, Ph.D., Associate Professor, Microbiology & Immunology at the University of Texas Medical Branch at Galveston, led the Alferon(R) N MERS-CoV experiments. Calu-3 cells were treated with Alferon(R) N 24 hours prior to infection with MERS-CoV. At 36 hours, supernatants were collected from cells and the virus titers were thereafter measured. Alferon(R) N showed significant dose-dependent inhibitory effects, thus suggesting the potential of Alferon(R) N as a preventative. Laboratory (in vitro) studies of potential antiviral agents are not necessarily predictive of clinical benefits. The Company supplied the Alferon N, but was not directly involved in the conduct of the experimentation. The results were forwarded to Hemispherx at the conclusion of the experiments for its review and formal publication is pending. The ability of Alferon N to inhibit replication of the MERS-CoV was also recently shown by experiments conducted at the National Institutes of Health (http://www.hemispherx.net/content/investor/default.asp?goto=781).
Hemispherx awarded new composition-of-matter patent for current and future ampligen formulations
M2 - Wed May 28, 3:06AM CDT
Pharmaceutical company Hemispherx Biopharma (NYSE MKT:HEB) disclosed on Tuesday the receipt of the US Patent 8,722,874 titled "Double-Stranded Ribonucleic Acids with Rugged Physiochemical Structure and Highly Specific Biologic Activity" from the US Patent Office.
Hemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen(R) Formulations
GlobeNewswire - Tue May 27, 8:27AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , announced that on May 13, 2014, the United States Patent Office issued U.S. Patent 8,722,874 titled "Double-Stranded Ribonucleic Acids with Rugged Physiochemical Structure and Highly Specific Biologic Activity" to inventors Carter, et al. and assignee Hemispherx Biopharma, Inc. The patent claims a novel form of rugged dsRNA. Rugged dsRNA are nucleic acids with a unique composition and physical characteristic identified with high specificity of binding to Toll-Like Receptor 3 (TLR3), thereby conveying an important range of therapeutic opportunities. The newly discovered form of dsRNA has increased bioactivity and binding affinity to the TLR 3 receptor because of its reduced tendency to form branched dsRNA, which can inhibit receptor binding. Pharmaceutical formulations containing the newly discovered nucleic acid as active ingredients, and methods of treatment with those formulations, are also described in the issued patent.
Hemispherx and GP Pharm Agree to Establish a Manufacturing Operation in Argentina to Serve Latin America Markets and Ancillary Markets
GlobeNewswire - Wed May 21, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , announced the preliminary stage agreement required to manufacture Ampligen(R) in Argentina in order to serve Latin American markets should Ampligen(R) be approved in Argentina. The aforementioned agreement is another important step moving forward in Argentina and South America pursuant to our Sales, Marketing, Distribution and Supply Agreement for Ampligen(R) with GP Pharm. The agreement is a prerequisite to the company starting the manufacture of stability lots, followed by stability testing, necessary to gain ANMAT's approval to manufacture Ampligen, contingent upon ANMAT approval. The parties are also actively discussing establishing a manufacturing capacity for Alferon(R) N in Argentina.
Hemispherx Biopharma Down 9.2%, Shares Slide into the Red (HEB)
Comtex SmarTrend(R) - Mon Mar 24, 10:41AM CDT
Hemispherx Biopharma (AMEX:HEB) is one of today's worst performing penny stocks, down 9.2% to $0.42 on 3.3x average daily volume. Thus far today, Hemispherx Biopharma has traded 5.3 million shares, vs. average volume of 1.6 million shares per day. The stock has underperformed the Dow (-9.2% to the Dow's -0.3%) and underperformed the S&P 500 (-9.2% to the S&P's -0.7%) during today's trading.
Hemispherx Biopharma, Inc. Presented Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference
GlobeNewswire - Mon Mar 24, 7:33AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) participated in the 11th Biennial International Research and Clinical Conference held in San Francisco, California, USA, on March 20-23, 2014. The title of the presentation was "Differential Exercise Responses to Rintatolimod [Ampligen(R)] Exhibited by Patients with Severe Chronic Fatigue Syndrome (CFS)". This Phase III prospective, double-blind, randomized, placebo-controlled trial was conducted at twelve centers by leading researchers in fatigue and post-exertional fatigue.
Traders Get Bullish on Shares of Hemispherx Biopharma, Shares Up 7.6% (HEB)
Comtex SmarTrend(R) - Thu Mar 20, 10:12AM CDT
Hemispherx Biopharma (AMEX:HEB) is one of today's best performing penny stocks, up 7.6% to $0.43 on 1.3x average daily volume. Hemispherx Biopharma has traded 2.1 million shares thus far today, vs. average volume of 1.6 million shares per day. The stock has outperformed the Dow (6.9% to the Dow's 0.3%) and outperformed the S&P 500 (6.9% to the S&P's 0.2%) during today's trading.
Momentum Indicators for Health Care Equities -- Research on Arena Pharma, Hemispherx Biopharma, PDL BioPharma and Celgene
PR Newswire - Thu Mar 20, 7:16AM CDT
The trading session on Wednesday, March 19, 2014 ended on a negative note as the S&P 500 finished at 1,860.77, down 0.61%; the NASDAQ Composite closed at 4,307.60, down 0.59%; the Dow Jones Industrial Average finished the session 0.70% lower at 16,222.17. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 686.44, down 0.37%, while the same has advanced 1.72% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Hemispherx Biopharma Inc. (AMEX: HEB), PDL BioPharma Inc. (NASDAQ: PDLI) and Celgene Corp. (NASDAQ: CELG). Free technical research on ARNA, HEB, PDLI and CELG can be downloaded upon signing up at:
Hemispherx Biopharma, Inc. to Present Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference
GlobeNewswire - Wed Mar 19, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) will participate in the 11th Biennial International Research and Clinical Conference to be held in San Francisco, California, USA, March 20-23, 2014. The title of the presentation is "Differential Exercise Responses to Rintatolimod [Ampligen(R)] Exhibited by Patients with Severe Chronic Fatigue Syndrome (CFS)". This Phase III prospective, double-blind, randomized, placebo-controlled trial was conducted at twelve centers by leading researchers in fatigue and post-exertional fatigue.
Hemispherx Biopharma posts lower net loss of USD16.225m in 2013
M2 - Mon Mar 17, 6:00AM CDT
Pharmaceutical company Hemispherx Biopharma (NYSE MKT:HEB) on Friday declared a net loss of about USD16.225m (USD0.10 per share) for the fiscal year ended 31 December 2013, including non-cash effects.
Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2013
GlobeNewswire - Fri Mar 14, 7:30AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the fiscal year ended December 31, 2013. The net loss for 2013's twelve month period (including non-cash effects) was approximately $16,225,000 or $(0.10) per share as compared to a net loss of $17,354,000 or ($0.12) per share for the same period in 2012. This year-to-year decrease in net loss was approximately $1,129,000 (7%), Cash, cash equivalents and marketable securities were approximately $18,194,000 as of December 31, 2013.
Hemispherx Biopharma Announces Plans to File for Regulatory Approval of Ampligen(R) to Treat Chronic Fatigue Syndrome (CFS) in Three Additional Latin America Countries
GlobeNewswire - Mon Mar 10, 10:00AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , announced that it and its partner in Latin America, GP Pharm, are planning on making applications in Chile, Peru and Uruguay for regulatory approval of Ampligen(R) to treat CFS.
Hemispherx Biopharma Wins Federal Lawsuit Regarding Investment Banking Fees
GlobeNewswire - Mon Mar 10, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company"or "Hemispherx" , announced that after more than a week in trial, a federal jury in Atlanta took only an hour to determine there was no merit to a brokerage firm's claim that Hemispherx owed the firm over $6 million for commissions from private sales of stock in 2009.
Stock to Watch: Hemispherx Biopharma Up 8.0% (HEB)
Comtex SmarTrend(R) - Tue Jul 22, 10:09AM CDT
Hemispherx Biopharma (AMEX:HEB) is one of today's best performing penny stocks, up 8.0% to $0.28 on 1.2x average daily volume. Hemispherx Biopharma has traded 831,000 shares thus far today, vs. average volume of 666,000 shares per day. The stock has outperformed the Dow (8.8% to the Dow's 0.4%) and outperformed the S&P 500 (8.8% to the S&P's 0.5%) during today's trading.
Hemispherx Achieves High Ranking in Sensitivity Testing Against MERS/SARS Coronaviruses Compared to Other Drugs
GlobeNewswire - Tue Jul 22, 7:31AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) announced that a new publication abstract in Infectious Disorder Drug Targets (2014 Jul 13. [Epub ahead of print]) is available for review as described in PubMed on July 16, 2014, and proposes that the Middle East Respiratory Syndrome (MERS)/(Severe Acute Respiratory Syndrome) SARS coronaviruses (CoV) may be most effectively inhibited by interferons (IFNs) and an IFN inducer (http://www.ncbi.nlm.nih.gov/pubmed/?term=Sensitivity+of+SARS%2FMERS+CoV+to+Interferons+and+Other+Drugs+Based+on+Achievable+Serum+Concentrations+in+Humans). The article, entitled "Sensitivity of SARS/MERS CoV to Interferons and Other Drugs Based on Achievable Serum Concentrations in Humans", is authored by Hemispherx scientists. It is suggested that correcting a viral induced defect in immunity may be the first significant way to decrease MERS/SARS associated mortality.
Hemispherx Biopharma and Bioclones, a Leading South African Biotechnology Company, Join Forces on Novel Therapeutic Cancer Vaccine
GlobeNewswire - Mon Jul 14, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announced a strategic alliance to develop multiple projects with Bioclones (Pty) Ltd. ("Bioclones" , a leading South African biotechnology company. Hemispherx Biopharma and Bioclones Join Forces in Effort to Eradicate HIV/AIDS Virus Based on Recent Clinical Insights of Wistar Institute, University of Pennsylvania
GlobeNewswire - Tue Jul 08, 8:23AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announced execution of an agreement to seek South African government approval to initiate a study of Alferon(R) N, the only FDA approved natural interferon, in the suppression of HIV Type 1 replication and the reduction/elimination of functional cell-associated HIV DNA integration (latent HIV). The study is contemplated as part of a broad strategic alliance with Bioclones (Pty) Ltd. ("Bioclones" , a leading South African biotechnology company. Hemispherx Biopharma to Present During the 2014 BIO International Convention June 26
GlobeNewswire - Wed Jun 25, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, will present a corporate update on their Advanced Therapies for the Human Immune System at 9:45 a.m. Pacific Time on June 26, during the 2014 BIO International Convention at the San Diego Convention Center. 5 Stocks Poised for Breakouts
at The Street - Fri Jun 13, 12:22PM CDT
These stocks look ready to break out and trade higher from current levels.
Hemispherx Announces That the University of Texas Medical Branch Confirms Activity of Alferon(R) N Against MERS (Middle East Respiratory Syndrome) Virus
GlobeNewswire - Tue Jun 03, 12:07PM CDT
Hemispherx Biopharma (NYSE MKT:HEB) announced that it has confirmed that one of its advanced stage biological products, Alferon(R) N, inhibits replication of the MERS virus in vitro. Chien-Te (Kent) Tseng, Ph.D., Associate Professor, Microbiology & Immunology at the University of Texas Medical Branch at Galveston, led the Alferon(R) N MERS-CoV experiments. Calu-3 cells were treated with Alferon(R) N 24 hours prior to infection with MERS-CoV. At 36 hours, supernatants were collected from cells and the virus titers were thereafter measured. Alferon(R) N showed significant dose-dependent inhibitory effects, thus suggesting the potential of Alferon(R) N as a preventative. Laboratory (in vitro) studies of potential antiviral agents are not necessarily predictive of clinical benefits. The Company supplied the Alferon N, but was not directly involved in the conduct of the experimentation. The results were forwarded to Hemispherx at the conclusion of the experiments for its review and formal publication is pending. The ability of Alferon N to inhibit replication of the MERS-CoV was also recently shown by experiments conducted at the National Institutes of Health (http://www.hemispherx.net/content/investor/default.asp?goto=781).
Hemispherx awarded new composition-of-matter patent for current and future ampligen formulations
M2 - Wed May 28, 3:06AM CDT
Pharmaceutical company Hemispherx Biopharma (NYSE MKT:HEB) disclosed on Tuesday the receipt of the US Patent 8,722,874 titled "Double-Stranded Ribonucleic Acids with Rugged Physiochemical Structure and Highly Specific Biologic Activity" from the US Patent Office.
Hemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen(R) Formulations
GlobeNewswire - Tue May 27, 8:27AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announced that on May 13, 2014, the United States Patent Office issued U.S. Patent 8,722,874 titled "Double-Stranded Ribonucleic Acids with Rugged Physiochemical Structure and Highly Specific Biologic Activity" to inventors Carter, et al. and assignee Hemispherx Biopharma, Inc. The patent claims a novel form of rugged dsRNA. Rugged dsRNA are nucleic acids with a unique composition and physical characteristic identified with high specificity of binding to Toll-Like Receptor 3 (TLR3), thereby conveying an important range of therapeutic opportunities. The newly discovered form of dsRNA has increased bioactivity and binding affinity to the TLR 3 receptor because of its reduced tendency to form branched dsRNA, which can inhibit receptor binding. Pharmaceutical formulations containing the newly discovered nucleic acid as active ingredients, and methods of treatment with those formulations, are also described in the issued patent. Hemispherx and GP Pharm Agree to Establish a Manufacturing Operation in Argentina to Serve Latin America Markets and Ancillary Markets
GlobeNewswire - Wed May 21, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announced the preliminary stage agreement required to manufacture Ampligen(R) in Argentina in order to serve Latin American markets should Ampligen(R) be approved in Argentina. The aforementioned agreement is another important step moving forward in Argentina and South America pursuant to our Sales, Marketing, Distribution and Supply Agreement for Ampligen(R) with GP Pharm. The agreement is a prerequisite to the company starting the manufacture of stability lots, followed by stability testing, necessary to gain ANMAT's approval to manufacture Ampligen, contingent upon ANMAT approval. The parties are also actively discussing establishing a manufacturing capacity for Alferon(R) N in Argentina. Hemispherx Biopharma Down 9.2%, Shares Slide into the Red (HEB)
Comtex SmarTrend(R) - Mon Mar 24, 10:41AM CDT
Hemispherx Biopharma (AMEX:HEB) is one of today's worst performing penny stocks, down 9.2% to $0.42 on 3.3x average daily volume. Thus far today, Hemispherx Biopharma has traded 5.3 million shares, vs. average volume of 1.6 million shares per day. The stock has underperformed the Dow (-9.2% to the Dow's -0.3%) and underperformed the S&P 500 (-9.2% to the S&P's -0.7%) during today's trading.
Hemispherx Biopharma, Inc. Presented Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference
GlobeNewswire - Mon Mar 24, 7:33AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) participated in the 11th Biennial International Research and Clinical Conference held in San Francisco, California, USA, on March 20-23, 2014. The title of the presentation was "Differential Exercise Responses to Rintatolimod [Ampligen(R)] Exhibited by Patients with Severe Chronic Fatigue Syndrome (CFS)". This Phase III prospective, double-blind, randomized, placebo-controlled trial was conducted at twelve centers by leading researchers in fatigue and post-exertional fatigue.
Traders Get Bullish on Shares of Hemispherx Biopharma, Shares Up 7.6% (HEB)
Comtex SmarTrend(R) - Thu Mar 20, 10:12AM CDT
Hemispherx Biopharma (AMEX:HEB) is one of today's best performing penny stocks, up 7.6% to $0.43 on 1.3x average daily volume. Hemispherx Biopharma has traded 2.1 million shares thus far today, vs. average volume of 1.6 million shares per day. The stock has outperformed the Dow (6.9% to the Dow's 0.3%) and outperformed the S&P 500 (6.9% to the S&P's 0.2%) during today's trading.
Momentum Indicators for Health Care Equities -- Research on Arena Pharma, Hemispherx Biopharma, PDL BioPharma and Celgene
PR Newswire - Thu Mar 20, 7:16AM CDT
The trading session on Wednesday, March 19, 2014 ended on a negative note as the S&P 500 finished at 1,860.77, down 0.61%; the NASDAQ Composite closed at 4,307.60, down 0.59%; the Dow Jones Industrial Average finished the session 0.70% lower at 16,222.17. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 686.44, down 0.37%, while the same has advanced 1.72% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Hemispherx Biopharma Inc. (AMEX: HEB), PDL BioPharma Inc. (NASDAQ: PDLI) and Celgene Corp. (NASDAQ: CELG). Free technical research on ARNA, HEB, PDLI and CELG can be downloaded upon signing up at:
Hemispherx Biopharma, Inc. to Present Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference
GlobeNewswire - Wed Mar 19, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) will participate in the 11th Biennial International Research and Clinical Conference to be held in San Francisco, California, USA, March 20-23, 2014. The title of the presentation is "Differential Exercise Responses to Rintatolimod [Ampligen(R)] Exhibited by Patients with Severe Chronic Fatigue Syndrome (CFS)". This Phase III prospective, double-blind, randomized, placebo-controlled trial was conducted at twelve centers by leading researchers in fatigue and post-exertional fatigue.
Hemispherx Biopharma posts lower net loss of USD16.225m in 2013
M2 - Mon Mar 17, 6:00AM CDT
Pharmaceutical company Hemispherx Biopharma (NYSE MKT:HEB) on Friday declared a net loss of about USD16.225m (USD0.10 per share) for the fiscal year ended 31 December 2013, including non-cash effects.
Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2013
GlobeNewswire - Fri Mar 14, 7:30AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the fiscal year ended December 31, 2013. The net loss for 2013's twelve month period (including non-cash effects) was approximately $16,225,000 or $(0.10) per share as compared to a net loss of $17,354,000 or ($0.12) per share for the same period in 2012. This year-to-year decrease in net loss was approximately $1,129,000 (7%), Cash, cash equivalents and marketable securities were approximately $18,194,000 as of December 31, 2013.
Hemispherx Biopharma Announces Plans to File for Regulatory Approval of Ampligen(R) to Treat Chronic Fatigue Syndrome (CFS) in Three Additional Latin America Countries
GlobeNewswire - Mon Mar 10, 10:00AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announced that it and its partner in Latin America, GP Pharm, are planning on making applications in Chile, Peru and Uruguay for regulatory approval of Ampligen(R) to treat CFS. Hemispherx Biopharma Wins Federal Lawsuit Regarding Investment Banking Fees
GlobeNewswire - Mon Mar 10, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company"or "Hemispherx"
, announced that after more than a week in trial, a federal jury in Atlanta took only an hour to determine there was no merit to a brokerage firm's claim that Hemispherx owed the firm over $6 million for commissions from private sales of stock in 2009. 
